Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000812066 | SCV000952368 | uncertain significance | Developmental and epileptic encephalopathy, 34 | 2022-08-09 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with SLC12A5-related conditions. ClinVar contains an entry for this variant (Variation ID: 655810). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces isoleucine, which is neutral and non-polar, with asparagine, which is neutral and polar, at codon 792 of the SLC12A5 protein (p.Ile792Asn). This variant is present in population databases (rs769820337, gnomAD 0.01%). |
Ambry Genetics | RCV004028757 | SCV003566342 | uncertain significance | not specified | 2021-08-09 | criteria provided, single submitter | clinical testing | The c.2444T>A (p.I815N) alteration is located in exon 18 (coding exon 18) of the SLC12A5 gene. This alteration results from a T to A substitution at nucleotide position 2444, causing the isoleucine (I) at amino acid position 815 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |